NSAIDs induce apoptosis in nonproliferating ovarian cancer cells and inhibit tumor growth in vivo

IUBMB Life

Volumn 64, Issue 7, 2012, Pages 636-643

  Duncan, Kristal ^a   Uwimpuhwe, Henriette ^a,b   Czibere, Akos ^c,d   Sarkar, Devanand ^e   Libermann, Towia A ^d   Fisher, Paul B ^e   Zerbini, Luiz F ^a,b  

^a International Center for Genetic Engineering and Biotechnology (ICGEB)   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d HARVARD MEDICAL SCHOOL   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

apoptosis; nonproliferating; NSAIDs; ovarian cancer; quiescence

Indexed keywords

CELECOXIB; FINASTERIDE; FLUFENAMIC ACID; FLURBIPROFEN; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC SULFIDE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENCY; FEMALE; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CANCER;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MICE; MICE, SCID; OVARIAN NEOPLASMS;

EID: 84862577007     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.1035     Document Type: Article

References (40)

1. Jemal, A., Siegel, R., Xu, J., and, Ward, E., (2010) Cancer statistics. CA Cancer J. Clin. 60, 277-300.
2. Tingulstad, S., Skjeldestad, F. E., Halvorsen, T. B., and, Hagen, B., (2003) Survival and prognostic factors in patients with ovarian cancer. Obstet. Gynecol. 101, 885-891.
3. Jackson, R. C., (1989) The problem of the quiescent cancer cell. Adv. Enzyme Regul. 29, 27-46.
4. Berges, R. R., Vukanovic, J., Epstein, J. I., CarMichel, M., Cisek, L., et al. (1995) Implication of cell kinetic changes during the progression of human prostatic cancer. Clin. Cancer Res. 1, 473-480.
5. Kondoh, E., Mori, S., Yamaguchi, K., Baba, T., Matsumura, N., et al. (2010) Targeting slow-proliferating ovarian cancer cells. Int. J. Cancer 126, 2448-2456.
6. Agarwal, R., and, Kaye, S. B., (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 3, 502-516.
7. Schindlbeck, C., Hantschmann, P., Zerzer, M., Jahns, B., Rjosk, D., et al. (2007) Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow. Int. J. Gynecol. Cancer 17, 1047-1055.
8. Mellor, H. R., Ferguson, D. J., and, Callaghan, R., (2005) A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs. Br. J. Cancer 93, 302-309.
9. Zinkel, S., Gross, A., and, Yang, E., (2006) BCL2 family in DNA damage and cell cycle control. Cell Death Differ. 13, 1351-1359.
10. Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348, 891-899.
11. Coogan, P. F., Rao, S. R., Rosenberg, L., Palmer, J. R., Strom, B. L., et al. (1999) The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev. Med. 29, 72-76.
12. Johnson, C. C., Hayes, R. B., Schoen, R. E., Gunter, M. J., and, Huang, W. Y., Non-steroidal anti-inflammatory drug use and colorectal polyps in the Prostate, Lung, Colorectal, And Ovarian Cancer Screening Trial. Am. J. Gastroenterol. 105, 2646-2655.
13. Cramer, D. W., Harlow, B. L., Titus-Ernstoff, L., Bohlke, K., Welch, W. R., et al. (1998) Over-the-counter analgesics and risk of ovarian cancer. Lancet 351, 104-107.
14. Rodriguez-Burford, C., Barnes, M. N., Oelschlager, D. K., Myers, R. B., Talley, L. I., et al. (2002) Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin. Cancer Res. 8, 202-209.
15. Wernli, K. J., Newcomb, P. A., Hampton, J. M., Trentham-Dietz, A., and, Egan, K. M., (2008) Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. Br. J. Cancer 98, 1781-1783.
16. Vane, J. R., and, Botting, R. M., (1998) Mechanism of action of antiinflammatory drugs. Int. J. Tissue React. 20, 3-15.
17. Zerbini, L. F., Tamura, R. E., Correa, R. G., Czibere, A., Cordeiro, J., et al. Combinatorial effect of non-steroidal anti-inflammatory drugs and NF-kappaB inhibitors in ovarian cancer therapy. PLoS One 6, e24285.
18. Zerbini, L. F., Czibere, A., Wang, Y., Correa, R. G., Otu, H., et al. (2006) A novel pathway involving melanoma differentiation associated gene-7/interleukin-24 mediates nonsteroidal anti-inflammatory drug-induced apoptosis and growth arrest of cancer cells. Cancer Res. 66, 11922-11931.
19. Jones, J. L., Daley, B. J., Enderson, B. L., Zhou, J. R., Karlstad, M. D., (2002) Genistein inhibits tamoxifen effects on cell proliferation and cell cycle arrest in T47D breast cancer cells. Am. Surg. 68, 575-577; discussion 577-578.
20. Masunaga, S., Nagasawa, H., Liu, Y., Sakurai, Y., Tanaka, H., et al. Evaluation of the radiosensitivity of the oxygenated tumor cell fractions in quiescent cell populations within solid tumors. Radiat. Res. 174, 459-466.
21. Steinbach, G., Lynch, P. M., Phillips, R. K., Wallace, M. H., Hawk, E., et al. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342, 1946-1952.
22. Bocca, C., Bozzo, F., Bassignana, A., Miglietta, A., (2011) Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines. Mol. Cell Biochem. 350, 59-70.
23. Din, F. V., Theodoratou, E., Farrington, S. M., Tenesa, A., Barnetson, R. A., et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 59, 1670-1679.
24. Ferrandina, G., Lauriola, L., Zannoni, G. F., Fagotti, A., Fanfani, F., et al. (2002) Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann. Oncol. 13, 1205-1211.
25. Denkert, C., Kobel, M., Pest, S., Koch, I., Berger, S., et al. (2002) Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am. J. Pathol. 160, 893-903.
26. Stoner, E., (1990) The clinical development of a 5 alpha-reductase inhibitor, finasteride. J. Steroid. Biochem. Mol. Biol. 37, 375-378.
27. Thompson, I. M., Klein, E. A., Lippman, S. M., Coltman, C. A., and, Djavan, B., (2003) Prevention of prostate cancer with finasteride: US/European perspective. Eur. Urol. 44, 650-655.
28. Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-McGinley, J., Walsh, P. C., et al. (1992) The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N. Engl. J. Med. 327, 1185-1191.
29. Quann, E. J., Khwaja, F., Zavitz, K. H., and, Djakiew, D., (2007) The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 67, 3254-3262.
30. Khwaja, F., Allen, J., Lynch, J., Andrews, P., and, Djakiew, D., (2004) Ibuprofen inhibits survival of bladder cancer cells by induced expression of the p75NTR tumor suppressor protein. Cancer Res. 64, 6207-6213.
31. Shaik, M. S., Chatterjee, A., Jackson, T., and, Singh, M., (2006) Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. Int. J. Cancer 118, 396-404.
32. Legge, F., Paglia, A., D'Asta, M., Fuoco, G., Scambia, G., et al. Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients. BMC Cancer 11, 214-222.
33. Lin, J., Hsiao, P. W., Chiu, T. H., and, Chao, J. I., (2005) Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. Biochem. Pharmacol. 70, 658-667.
34. Chan, A. T., Manson, J. E., Feskanich, D., Stampfer, M. J., Colditz, G. A., et al. (2007) Long-term aspirin use and mortality in women. Arch Intern. Med. 167, 562-572.
35. Jacobs, E. J., Thun, M. J., Bain, E. B., Rodriguez, C., Henley, S. J., et al. (2007) A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J. Natl. Cancer Inst. 99, 608-615.
36. Duffy, C. P., Elliott, C. J., O'Connor, R. A., Heenan, M. M., Coyle, S., et al. (1998) Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur. J. Cancer 34, 1250-1259.
37. El-Rayes, B. F., Zalupski, M. M., Manza, S. G., Rusin, B., Ferris, A. M., et al. 2008 Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. Cancer Chemother. Pharmacol. 61, 283-289.
38. Maiello, E., Giuliani, F., Gebbia, V., Di Renzo, N., Pezzella, G., et al. (2006) FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Ann. Oncol. 17 (Suppl 7), vii55-vii59.
39. Wechter, W. J., Leipold, D. D., Murray, E. D., Jr., Quiggle, D., McCracken, J. D., et al. (2000) E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res. 60, 2203-2208.
40. Wechter, W. J., Kantoci, D., Murray, E. D., Jr., Quiggle, D. D., Leipold, D. D., et al. (1997) R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: implications for prophylaxis and treatment of colon cancer. Cancer Res. 57, 4316-4324.